Montgomery Street

Eliem Therapeutics Announces Pricing of Initial Public Offering

Retrieved on: 
Tuesday, August 10, 2021
808, U.S. Securities and Exchange Commission, Madison Avenue, GLOBE, LLC, Sale, Suite, Therapy, State Street, Psychiatry, Equity capital markets, Epilepsy, Floor, Guggenheim Partners, Nasdaq, Telephone, SVB Leerink, Montgomery Street, SEC, Prospectus, Exercise, Company, Guggenheim, Security (finance), Attention, Chronic pain

SEATTLE and CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced the pricing of its initial public offering of 6,400,000 shares of common stock at a public offering price of $12.50 per share.

Key Points: 
  • SEATTLE and CAMBRIDGE, United Kingdom, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced the pricing of its initial public offering of 6,400,000 shares of common stock at a public offering price of $12.50 per share.
  • Eliem has granted the underwriters a 30-day option to purchase up to an additional 960,000 shares of common stock at the initial public offering price.
  • The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Eliem, are expected to be $80.0 million, excluding any exercise of the underwriters option to purchase additional shares of common stock.
  • The offering will be made only by means of a written prospectus, forming a part of the effective registration statements.

VIQ Solutions Announces Proposed Public Offering of Common Shares in the United States and Canada and Update Timing of Nasdaq Listing

Retrieved on: 
Monday, August 9, 2021
Technology, Professional Services, Other Communications, Security, Telecommunications, Communications, Software, Audio, Video, Networks, Internet, Legal, Mobile, Wireless, Hardware, Insurance, Data Management, Finance, Consumer Electronics, Toronto Stock Exchange, Solution, Acquisition, Indian stock exchange, Stikeman Elliott, McMillan LLP, Montgomery Street, Forward-looking statement, OTCQX, LLP, Exercise, Bangladesh Securities and Exchange Commission, SEDAR, Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo, COVID-19, Government, Park Avenue, Security (finance), U.S. Securities and Exchange Commission, Prospectus, Needham & Company, Retail Solutions Inc., LLC, Sale, Industry, Needham, News, Form, SEC, TSX, Legislation, Insurance, VQS, Company, Offering, McMillan, Suite, Telephone, VIQ, Attention, Mobile phone, Risk management

Trading of the Common Shares on the Nasdaq Capital Market (Nasdaq) is expected to commence under the ticker symbol VQS on the trading day immediately following the pricing of the Common Shares under the Offering.

Key Points: 
  • Trading of the Common Shares on the Nasdaq Capital Market (Nasdaq) is expected to commence under the ticker symbol VQS on the trading day immediately following the pricing of the Common Shares under the Offering.
  • The Over-Allotment Option will be exercisable by the Underwriters for a period of 30 days following the closing of the Offering.
  • The short form base shelf prospectus and the related prospectus supplement contain important information about the Common Shares.
  • VIQ is represented by McMillan LLP in Canada and Troutman Pepper Hamilton Sanders LLP in the United States.

Adagio Therapeutics Announces Pricing of Initial Public Offering

Retrieved on: 
Friday, August 6, 2021
Biotechnology, Pharmaceutical, Health, Jefferies Group, Company, 2nd Floor (Nina song), U.S. Securities and Exchange Commission, Attention, Prospectus, Varick Street, Security (finance), Risk, Therapy, Morgan Stanley, Nasdaq, Sale, Jefferies, LLC, Guggenheim Partners, Suite, Infection, Floor, Madison Avenue, Montgomery Street, Telephone

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced the pricing of its initial public offering of 18,200,000 shares of common stock at a price to the public of $17.00 per share.

Key Points: 
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced the pricing of its initial public offering of 18,200,000 shares of common stock at a price to the public of $17.00 per share.
  • The gross proceeds to Adagio from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $309.4 million.
  • In addition, Adagio has granted the underwriters a 30-day option to purchase up to an additional 2,730,000 shares of its common stock at the initial public offering price less the underwriting discounts and commissions.
  • This press release contains certain forward-looking statements, including statements with regard to Adagios proposed securities offering.

Rapid Micro Biosystems Announces Exercise and Closing of Over-Allotment Option in Initial Public Offering

Retrieved on: 
Wednesday, August 4, 2021
Company, Broadridge Financial Solutions, Prospectus, Form S-1, U.S. Securities and Exchange Commission, Telephone, Automation, Limited liability company, Enterprise file synchronization and sharing, Suite, Form, Sale, Montgomery Street, 2nd Floor (Nina song), Nasdaq, Exercise, Attention, Varick Street, Security (finance), GLOBE

The exercise of the over-allotment option closed on August 4, 2021.

Key Points: 
  • The exercise of the over-allotment option closed on August 4, 2021.
  • J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers of the offering.
  • 333-257431) relating to the offering has been filed with the Securities and Exchange Commission and became effective on July 14, 2021.
  • The offering will be made only by means of a prospectus.

Aegon sells the Pyramid building complex in San Francisco

Retrieved on: 
Thursday, October 29, 2020
Commercial Building & Real Estate, Construction & Property, Professional services, Finance, Financial District, San Francisco, Aegon, Montgomery Street, Michael Shvo, Transamerica, Business, Industries, San Francisco, Transamerica Pyramid, Aegon N.V.

Transamerica, Aegons business in the United States, has sold the Pyramid building complex which includes the Pyramid, 505 Sansome, the Redwood Park and other properties in the block bounded by Montgomery Street, Clay Street, Washington Street, and Sansome Street in San Francisco, to a joint venture led by Michael Shvo.

Key Points: 
  • Transamerica, Aegons business in the United States, has sold the Pyramid building complex which includes the Pyramid, 505 Sansome, the Redwood Park and other properties in the block bounded by Montgomery Street, Clay Street, Washington Street, and Sansome Street in San Francisco, to a joint venture led by Michael Shvo.
  • I am pleased that we have taken another step to strengthen our balance sheet with the sale of the Pyramid building complex, commented Lard Friese, CEO of Aegon.
  • Since then, Aegon has grown into an international company, with businesses in more than 20 countries in the Americas, Europe and Asia.
  • Today, Aegon is one of the worlds leading financial services organizations, providing life insurance, pensions and asset management.